Marker Therapeutics, Inc.SEC Filings
|
|
All SEC filings by Marker Therapeutics, Inc. (MRKR) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 14, 2026 | |
| 10-Q | Quarterly report | View Diff | May 15, 2026 | |
| ARS | Annual report to shareholders | Mar 20, 2026 | ||
| 10-K | Annual report | View Diff | Mar 18, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 13, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 14, 2025 | |
| 10-Q | Quarterly report | View Diff | May 15, 2025 | |
| ARS | Annual report to shareholders | Apr 24, 2025 | ||
| 10-K | Annual report | View Diff | Mar 31, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2024 |
Events
| 8-K | Amendments to Articles of Incorporation or Bylaws | May 4, 2026 | ||
| 8-K | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results | Mar 18, 2026 | ||
| 8-K | Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 | Feb 9, 2026 | ||
| 8-K | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Nov 14, 2025 | ||
| 8-K | Marker Therapeutics Appoints Kathryn Penkus Corzo to Board of Directors | Nov 5, 2025 | ||
| 8-K | Marker Therapeutics Announces First Patient Treated in Off-The-Shelf Program | Oct 6, 2025 | ||
| 8-K | Marker Therapeutics Provides Update on Phase 1 Apollo Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma | Aug 26, 2025 | ||
| 8-K | Changes in Registrant'S Certifying Accountant | Aug 12, 2025 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jun 17, 2025 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | Jun 9, 2025 |
Registrations and Prospectuses
| 424B7 | Prospectus with selling stockholder info | Aug 5, 2025 | ||
| 424B3 | Prospectus supplement | Jan 17, 2025 | ||
| S-3 | Shelf registration | View Diff | Jan 10, 2025 | |
| D | $16.10 Mm in Equity / Securities to Be Acquired, Sold $16.10 Mm, 5 Investors | Dec 30, 2024 | ||
| 424B3 | Prospectus supplement | Dec 6, 2024 | ||
| S-3 | Shelf registration | Nov 27, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 22, 2023 | ||
| 424B3 | Prospectus supplement | Jan 3, 2023 | ||
| S-1 | IPO registration | Dec 23, 2022 | ||
| S-8 | Registration of securities for employees | Aug 11, 2022 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Mar 20, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 20, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Mar 10, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 24, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 24, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Feb 4, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Feb 4, 2025 | |
| PRE 14A | Preliminary proxy | View Diff | Jan 13, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Apr 26, 2024 | |
| DEF 14A | Definitive proxy | View Diff | Apr 28, 2023 |
Other
| EFFECT | Notice of effectiveness | Jan 21, 2025 | ||
| UPLOAD | Letter from SEC | Jan 15, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 15, 2025 | ||
| EFFECT | Notice of effectiveness | Dec 9, 2024 | ||
| CORRESP | Correspondence with SEC | Dec 4, 2024 | ||
| UPLOAD | Letter from SEC | Dec 4, 2024 | ||
| EFFECT | Notice of effectiveness | Jan 3, 2023 | ||
| CORRESP | Correspondence with SEC | Dec 29, 2022 | ||
| UPLOAD | Letter from SEC | Dec 29, 2022 | ||
| EFFECT | Notice of effectiveness | Aug 20, 2021 |
Ownership
| 4 | Katharine Knobil | Nov 19, 2025 | ||
| 4 | Norman David Eansor | Nov 19, 2025 | ||
| 4 | Steve Elms | Nov 19, 2025 | ||
| SC 13D/A | Marker Therapeutics, Inc. | Nov 17, 2025 | ||
| SC 13G/A | Marker Therapeutics, Inc. | Nov 14, 2025 | ||
| 4 | Kathryn Penkus Corzo | Nov 4, 2025 | ||
| 4 | Juan Vera | Nov 4, 2025 | ||
| 3 | Kathryn Penkus Corzo | Nov 4, 2025 | ||
| SC 13D/A | Marker Therapeutics, Inc. | Aug 20, 2025 | ||
| SC 13D/A | Marker Therapeutics, Inc. | Aug 19, 2025 |